CureToday: UC enrolling patients for glioblastoma trial
A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.
Soma Sengupta, MD, PhD, said the trial will administer two immunotherapy drugs in tandem with each other. She noted previous research has shown a single-arm immunotherapy treatment has not been effective, leading to the combination therapy being tested in the trial.
In collaboration with the Dana-Farber Cancer Insitute in Boston, a teaching affiliate of Harvard Medical School, researchers aim to enroll 24 patients in the Phase 1 study.
For more trial and enrollment information, contact Alex Love at lovea4@ucmail.uc.edu.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
Takeaways from conversations with wrongfully convicted Ohio...
November 20, 2024
Public radio journalist Mary Evans casts a spotlight on wrongful conviction and the work of the Ohio Innocence Project at UC Law.
Why can it be so tough to find health care for adults with...
November 20, 2024
Everyone needs to go to a doctor from time to time. But for adults with disabilities, finding a medical provider can be a challenge. A 2022 study found some doctors try to avoid treating patients with disabilities because of feeling overwhelmed and inadequately reimbursed for accommodations they need to provide.
UC Cancer Center uses AI to enhance early lung cancer detection
November 20, 2024
Local 12 highlighted how artificial intelligence technology is helping University of Cincinnati Cancer Center experts improve early detection of lung cancer, potentially saving lives by identifying suspicious findings sooner.